Learn the 7 vital bladder cancer warning signs that require immediate medical attention, including subtle early symptoms many ...

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The presence of residual tumor cells in the trigone and urethra after robot-assisted radical cystectomy (RARC) is associated with a higher tumor stage, positive margins, and cancer recurrence compared ...

Bladder cancer spreads at different speeds depending on the type of bladder cancer you have. Urothelial bladder cancer is slow to spread, while other types are much faster. Urothelial bladder ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Army bomb disposal veterans may have a significantly increased risk of developing bladder cancer compared to the general ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...